Pfiz­er plans an­oth­er $500M in cost cuts, ex­pects $3.1B in rev­enue from Seagen in 2024

Pfiz­er’s not-so-good year con­tin­ues.

The New York phar­ma gi­ant’s shares $PFE slid 7% be­fore Wednes­day’s open­ing bell af­ter Pfiz­er said it plans to cut an­oth­er $500 mil­lion in costs, on top of the $3.5 bil­lion plan dis­closed in Oc­to­ber, and Seagen’s can­cer treat­ments would con­tribute $3.1 bil­lion to Pfiz­er’s ex­pect­ed full-year 2024 rev­enue.

Pfiz­er ex­pects to close the Seagen ac­qui­si­tion on Thurs­day af­ter ini­tial­ly re­veal­ing the deal in March. The ac­qui­si­tion is a bid to dou­ble its on­col­o­gy pipeline and add a slate of mar­ket­ed med­i­cines from the an­ti­body-drug con­ju­gate pi­o­neer. Half of the new Pfiz­er On­col­o­gy lead­er­ship will be lega­cy Pfiz­er em­ploy­ees and the oth­er half will be from Seagen, per an in­vestor pre­sen­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER